a. The boundaries of a narrower basketball court with all other dimensions being the same as a conventional court.
b. The decision to make a tennis court narrower has resulted in a bifurcation of the of the game into two different categories of tennis, single and doubles, played throughout the world in millions of formal and informal matches. A basketball court using the same logic could make a narrower court game equally as challenging and popular.
c. The game provides a greater challenge in that the players are running up and down the court giving them a better workout as a form of exercise.
d. The full court format also challenges the players basketball skill and can translate into a learning activity which help improve performance especially ball handling skills.
e. The full court narrower court increases the time spent running during the game improving the players endurance and stamina.
f. The narrower court also makes it more challenging and enjoyable for playing a full court two on two game.
g. The narrower court makes it more challenging and enjoyable for playing a full court three on three game.
h. The narrower court makes it more challenging and enjoyable for playing a full court four on four game.
i. The narrower court can be an incentive for people to exercise since merely jogging or running becomes boring to some people as compared to a game sport.
j. Though there are no physical restrictions on a full court game on a court with a standard with, and millions of games of one on one basketball are played every year rarely do players play full court but opt for a half court format.
j. The novelty of full court one on one on a narrower court is that it plays like a five on five game on a court with conventional boundaries.
k. Narrowing the boundaries is not obvious since millions of courts exists, the games advantages are numerous and adding the additional boundaries on a court is of little costs.
l. The boundaries can be as narrow as the width on the sides of the 3 second lane. Or within a foot of the conventional court width. Or any dimension in between.
m. The game can also be played with a rule to restrict the offensive player from shooting the initial shot on a time down court within the lane or 3 second area. After an initial attempt subsequent shots can be shot from within the lane area.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of accessing the aggressiveness of a breast cancer in a subject comprising
a) detecting the level of protein expression of AE1AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2) in a formalin fixed, paraffin-embedded tumor tissue sample from the subject, and
b) comparing the level of protein expression to a reference value.
2. The method of claim 1, wherein said method discriminated between a Her2(2+) tumor and a Her2(3+) tumor.
3. A method of accessing the effectiveness of a treatment regimen of a subject having breast cancer comprising
a) detecting the level of protein expression of AE1AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2 in a formalin fixed, paraffin-embedded tumor tissue sample from the subject, and
b) comparing the level of protein expression to a reference value.
4. A method of monitoring a treatment regimen of a subject with breast cancer comprising
a) detecting the level of protein expression of AE1AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2) in a tumor sample from the subject at a first period of time;
b) detecting the level of protein expression of AE1AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2) in a formalin fixed, paraffin-embedded tumor tissue sample from the subject at a second period of time;
c) comparing the amount of protein expression detected in step (a) to the amount detected in step (b), or to a reference value.
5. A method of determining whether a subject with breast cancer would derive a benefit from a treatment regimen
a) detecting the level of protein expression of AE1AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2) in a formalin fixed, paraffin-embedded tumor tissue sample from the subject, and
b) comparing the level of protein expression to a reference value.
6. The method of claim 3, wherein said treatment is immunotherapy.
7. The method of claim 6, wherein said immunotherapy is trastuzumab, bevacizumab or lapatainib.
8. A method of determining the amount of p95HER2 in a formalin fixed, paraffin-embedded tumor tissue sample from the subject
a) detecting the level of protein expression of TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2) in the sample;
b) combining the expression levels of Her2 and pHer2 obtained in step (a) to produce a combined value;
c) subtracting the expression level of TAB250 obtained in step (a) from the combined value obtained in step (b).
9. A method for predicting the survivability of a breast cancer-diagnosed subject comprising
a) detecting the level of protein expression of AE1AE3 (cytokeratin), TAB250 (Her2-ECD), c-erb B2 (Her2) and phosphorylated Her 2 (pHer2) in a formalin fixed, paraffin-embedded tumor tissue sample from the subject, and
b) comparing the level of protein expression to a reference value.
10. The method of claim 1, wherein the level of protein expression is detected by immunoflourescence.
11. A method of evaluating the survivability of a breast-cancer diagnosed subject, the method comprising:
evaluating a dataset for a subject with a model predictive of breast cancer survivability, wherein the model is based on one or more features selected from the following group of features: tumor size, multifocalilty, surgical margin involvement, vesselperineural invasion, necrosis, histological type, Bloom-Ricahrdosn grade, lymph node status, intraductal status, fibrocystics status, micro-calcifications, c-erb B2 (Her2) (HER2) staining index of tumor, phosphorylated Her 2 (pHer2) staining index of tumor a morphometric measurement of epithelial nuclei derived from a tissue image, andor a morphometric measurement of stroma derived from a tissue image,
thereby evaluating the survivability of a breast-cancer diagnosed subject.
12. The method of claim 11, further comprising outputting a value indicative of the subjects’s survivability
13. A computer-readable medium comprising computer executable instructions recorded thereon for performing the method comprising: evaluating a dataset for a patient with a model predictive of breast cancer survivability to thereby evaluate the survivability of the patient, wherein the model is based on one or more features selected from the following group of features: wherein the model is based on one or more features selected from the following group of features: tumor size, multifocalilty, surgical margin involvement, vesselperineural invasion, necrosis, histological type, Bloom-Ricahrdosn grade, lymph node status, intraductal status, fibrocystics status, micro-calcifications, c-erb B2 (Her2) (HER2) staining index of tumor, phosphorylated Her 2 (pHer2) staining index of tumor, a morphometric measurement of epithelial nuclei derived from a tissue image, andor a morphometric measurement of stroma derived from a tissue image.